In the last trading session, 3.13 million Aligos Therapeutics Inc (NASDAQ:ALGS) shares changed hands as the company’s beta touched 2.11. With the company’s per share price at $13.99 changed hands at $3.8 or 37.29% during last session, the market valuation stood at $94.22M. ALGS’s last price was a discount, traded about -114.44% off its 52-week high of $30.00. The share price had its 52-week low at $6.76, which suggests the last value was 51.68% up since then. When we look at Aligos Therapeutics Inc’s average trading volume, we note the 10-day average is 0.14 million shares, with the 3-month average coming to 97.78K.

Analysts gave the Aligos Therapeutics Inc (ALGS) stock a consensus recommendation rating of Hold, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 2 out of 9 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 4 recommended ALGS as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Aligos Therapeutics Inc’s EPS for the current quarter is expected to be -2.63.

Aligos Therapeutics Inc (NASDAQ:ALGS) trade information

Instantly ALGS was in green as seen at the end of in last trading. With action 47.57%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -15.72%, with the 5-day performance at 47.57% in the green. However, in the 30-day time frame, Aligos Therapeutics Inc (NASDAQ:ALGS) is 83.60% up. Looking at the short shares, we see there were 82817.0 shares sold at short interest cover period of 0.82 days.

The consensus price target for the stock as assigned by Wall Street analysts is 3, meaning bulls need a downside of -366.33% from its current market value. According to analyst projections, ALGS’s forecast low is 3 with 3 as the target high. To hit the forecast high, the stock’s price needs a 78.56% surge from its current level, while the stock would need to tank 78.56% for it to hit the projected low.

Aligos Therapeutics Inc (ALGS) estimates and forecasts

Data shows that the Aligos Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -18.26% over the past 6 months, a 71.12% in annual growth rate that is considerably higher than the industry average of 16.80%. Year-over-year growth is forecast to reach -64.40% down from the last financial year.

Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 430k. 3 analysts are of the opinion that Aligos Therapeutics Inc’s revenue for the current quarter will be 330k. The company’s revenue for the corresponding quarters a year ago was 2.01M and 986k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -78.60%. The estimates for the next quarter sales put growth at -66.50%.

The 2024 estimates are for Aligos Therapeutics Inc earnings to increase by 70.31%.

ALGS Dividends

Aligos Therapeutics Inc is expected to release its next quarterly earnings report in December.

Aligos Therapeutics Inc (NASDAQ:ALGS)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 20.07% of Aligos Therapeutics Inc shares while 65.59% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 82.05%. There are 65.59% institutions holding the Aligos Therapeutics Inc stock share, with ARMISTICE CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 4.6471% of the shares, roughly 7.26 million ALGS shares worth $2.54 million.

ECOR1 CAPITAL, LLC holds the second largest percentage of outstanding shares, with 4.0919% or 6.39 million shares worth $2.24 million as of 2024-06-30.